RESUMEN
Purpose: To investigate the efficacy and safety of selective intra-ophthalmic arterial combined nimodipine and alteplase infusion in patients with central retinal artery occlusion (CRAO). Design: Non-randomized, prospective interventional study. Methods: All patients with CRAO who presented at our institute within 24 hours from CRAO onset from August 2020 to July 2022 were included. Intra-arterial nimodipine and alteplase were given selectively into the ophthalmic artery. Visual acuity was recorded during and after the procedure. Change in best corrected visual acuity (BCVA) 1 month post-treatment, relative to baseline, was set as the primary outcome measure. Significant improvement in vision and adverse events are reported as secondary outcomes. Patients: Nine patients with non-arteritic CRAO were enrolled. Results: A total of nine patients with CRAO underwent selective intra-ophthalmic arterial nimodipine and alteplase injection. Overall, BCVA had statistically significantly improved by 0.78 logarithm of the minimum angle of resolution (logMAR) at 1 month compared with baseline (95% confidence interval: (-1.24, -0.31), p-value = 0.001). Seven (77.8%) patients had significant visual improvement (≥0.3 logMAR) at 1-month post-treatment. There were minor adverse events during administration of the nimodipine, including chemosis and headache, which resolved after the discontinuation of nimodipine. There were also asymptomatic thromboembolic events in 2 patients (22.2%) after the intervention procedure, without any morbidity or mortality. Conclusion: The use of selective intra-ophthalmic arterial combined nimodipine and alteplase was efficacious in improving BCVA at 1 month for patients with non-arteritic CRAO presenting between 24 hours from onset, with minor adverse events but no serious adverse events.
RESUMEN
BACKGROUND: Spinal arteriovenous shunts are rare diseases. Different classifications have been proposed, but the most widely used are those classified by locations. Different locations (i.e., intramedullary and extramedullary) have different treatment outcomes and different posttreatment angiographical results. Our study presents the 15-year endovascular treatment outcomes of patients who had spinal extramedullary arteriovenous fistulas (AVFs) at Ramathibodi Hospital, which is a tertiary care hospital in Thailand. METHODS: A retrospective medical record and imaging review of all patients with spinal extramedullary AVFs, which were confirmed by a diagnostic spinal angiogram in our institute from January 2006 to December 2020, were performed. The angiographic complete obliteration rate in the first session of endovascular treatment, clinical outcomes of the patients, and complications of the procedures for all eligible patients were analyzed. RESULTS: Sixty-eight eligible patients were included in the study. The most common diagnosis was spinal dural AVF (45.6%). The most common presenting symptoms were weakness, numbness, and bowel-bladder involvement (70.6%, 67.6%, and 57.4%, respectively). Ninety-four percent had spinal cord edema in preoperative magnetic resonance imaging. All patients had pial venous reflux. Sixty-four patients (94.1%) received endovascular treatment as the first option. The complete obliteration rate in the first session of endovascular treatment was 75% and was high in all subgroups except for the perimedullary AVF group. The overall intraoperative complication of endovascular treatment was 9.4%. Follow-up imaging showed no residual AVF in 50 patients (87.7%). Most of the patients (57.4%) had improvement of neurological functions at 3- to 6-month follow-up. CONCLUSION: Treatment results of spinal extramedullary AVFs were good in terms of angiographic aspects and clinical outcomes. This may have resulted from the locations of the AVFs, which mostly did not involve the spinal cord arterial supply, with the exception of perimedullary AVFs. Although perimedullary AVF is difficult to treat, it can be cured by careful catherization and embolization.